Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

Moghaddam B, Javitt D.

Neuropsychopharmacology. 2012 Jan;37(1):4-15. doi: 10.1038/npp.2011.181. Epub 2011 Sep 28. Review.

PMID:
21956446
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Glutamate as a therapeutic target in psychiatric disorders.

Javitt DC.

Mol Psychiatry. 2004 Nov;9(11):984-97, 979. Review.

PMID:
15278097
[PubMed - indexed for MEDLINE]
3.

N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Kantrowitz JT, Javitt DC.

Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006. Epub 2010 Apr 24. Review.

PMID:
20417696
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks.

Menniti FS, Lindsley CW, Conn PJ, Pandit J, Zagouras P, Volkmann RA.

Curr Top Med Chem. 2013;13(1):26-54. Review.

PMID:
23409764
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.

Noetzel MJ, Jones CK, Conn PJ.

Discov Med. 2012 Nov;14(78):335-43. Review.

PMID:
23200065
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs.

WieroĊ„ska JM, Pilc A.

Neurochem Int. 2009 Jul-Aug;55(1-3):85-97. doi: 10.1016/j.neuint.2009.02.019. Epub 2009 Mar 9. Review.

PMID:
19428811
[PubMed - indexed for MEDLINE]
7.

Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission.

Hui C, Wardwell B, Tsai GE.

Recent Pat CNS Drug Discov. 2009 Nov;4(3):220-38. Review.

PMID:
19891601
[PubMed - indexed for MEDLINE]
8.

Glutamatergic aspects of schizophrenia.

Tamminga C.

Br J Psychiatry Suppl. 1999;(37):12-5. Review.

PMID:
10211134
[PubMed - indexed for MEDLINE]
9.

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Javitt DC.

Int Rev Neurobiol. 2007;78:69-108. Review.

PMID:
17349858
[PubMed - indexed for MEDLINE]
10.

Glutamatergic theories of schizophrenia.

Javitt DC.

Isr J Psychiatry Relat Sci. 2010;47(1):4-16. Review.

PMID:
20686195
[PubMed - indexed for MEDLINE]
Free Article
11.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

PMID:
19933774
[PubMed - indexed for MEDLINE]
Free Article
12.

Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Coyle JT, Basu A, Benneyworth M, Balu D, Konopaske G.

Handb Exp Pharmacol. 2012;(213):267-95. doi: 10.1007/978-3-642-25758-2_10. Review.

PMID:
23027419
[PubMed - indexed for MEDLINE]
13.

Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.

Pietraszek M.

Pol J Pharmacol. 2003 Mar-Apr;55(2):133-54. Review.

PMID:
12926541
[PubMed - indexed for MEDLINE]
Free Article
14.

Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.

Gaspar PA, Bustamante ML, Silva H, Aboitiz F.

J Neurochem. 2009 Nov;111(4):891-900. doi: 10.1111/j.1471-4159.2009.06325.x. Epub 2009 Aug 4. Review.

PMID:
19686383
[PubMed - indexed for MEDLINE]
15.

Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.

Deakin FW, Simpson MD, Slater P, Hellewell JS.

J Psychopharmacol. 1997;11(2):133-42. Review.

PMID:
9254279
[PubMed - indexed for MEDLINE]
16.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
[PubMed - indexed for MEDLINE]
17.

The chemical biology of clinically tolerated NMDA receptor antagonists.

Chen HS, Lipton SA.

J Neurochem. 2006 Jun;97(6):1611-26. Review.

PMID:
16805772
[PubMed - indexed for MEDLINE]
18.

[Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].

Hashimoto K, Iyo M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Feb;22(1):3-13. Review. Japanese.

PMID:
11917507
[PubMed - indexed for MEDLINE]
19.

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

Stone JM.

Curr Pharm Des. 2009;15(22):2594-602. Review.

PMID:
19689330
[PubMed - indexed for MEDLINE]
20.

Twenty-five years of glutamate in schizophrenia: are we there yet?

Javitt DC.

Schizophr Bull. 2012 Sep;38(5):911-3. doi: 10.1093/schbul/sbs100.

PMID:
22987849
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk